Anthera Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company's loss from operations was $16,600,000 compared to $11,350,000 a year ago. Net loss was $16,478,000 or $0.61 per basic and diluted share compared to $11,326,000 or $0.29 per basic and diluted share a year ago. For the nine months, the company's total revenues were $145,000 compared to $1,267,000 a year ago. Loss from operations was $42,598,000 compared to $27,853,000 a year ago. Net loss was $42,538,000 or $1.25 per basic and diluted share compared to $27,881,000 or $0.81 per basic and diluted share a year ago. The increase in net loss is mainly attributable to the increase in manufacturing expense for Sollpura™ and clinical study expense for both Sollpura and blisibimod in 2016.